Tocilizumab for systemic sclerosis: implications for future trials.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  The Lancet

• Publication date

  2016-06-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(16)00622-XPMID 27156931
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.

  2016cited by this paper
• From pathogenesis to therapy--Perspective on treatment strategies in fibrotic diseases.

  2015cited by this paper
• Macrophages During the Fibrotic Process: M2 as Friend and Foe

  2015cited by this paper
• Systemic sclerosis and localized scleroderma—current concepts and novel targets for therapy

  2015cited by this paper
• Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database.

  2015cited by this paper
• Personalized Medicine in Systemic Sclerosis: Facts and Promises

  2014cited by this paper
• Macrophage biology in development, homeostasis and disease

  2013cited by this paper
• Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors

  2013cited by this paper
• Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies

  2012cited by this paper
• Macrophages: Master Regulators of Inflammation and Fibrosis

  2010cited by this paper
• EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)

  2009cited by this paper
• CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis.

  2007cited by this paper
• CCL 18 as an Indicator of Pulmonary Fibrotic Activity in Idiopathic Interstitial Pneumonias and Systemic Sclerosis

  2007cited by this paper

• Coexistence of Localized and Systemic Juvenile Scleroderma: A Case Report and Review of Literature

  2025cites this paper
• Therapeutic management of fibrosis in systemic sclerosis patients - an analysis from the Swiss EUSTAR cohort.

  2024cites this paper
• Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort

  2022cites this paper
• Expert Perspectives On Clinical Challenges: Expert Perspectives: Challenges in Scleroderma

  2020cites this paper
• Infections and systemic sclerosis: an emerging challenge

  2020cites this paper
• Parry Romberg disease with En Coup de Sabre Scleroderma: Effect of tocilizumab on periodontal bone inflammation

  2020cites this paper
• Infecciones y esclerosis sistémica: un desafío emergente

  2020cites this paper
• Macrophages Guard Endothelial Lineage by Hindering Endothelial-to-Mesenchymal Transition: Implications for the Pathogenesis of Systemic Sclerosis

  2019cites this paper
• Frontiers of antifibrotic therapy in systemic sclerosis

  2018cites this paper
• Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)

  2017cites this paper
• Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages

  2017cites this paper
• Use of biologics and other novel therapies for the treatment of systemic sclerosis

  2017cites this paper
• Tocilizumab is a promising treatment option for therapy resistant juvenile localized scleroderma patients

  2017cites this paper
• Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis

  2017cites this paper
• Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis

  2016cites this paper
• One year in review 2016: systemic sclerosis.

  2016cites this paper